Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD)
Titel:
Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD)
Auteur:
Yu, Helena A. Goldberg, Sarah B. Le, Xiuning Piotrowska, Zofia Goldman, Jonathan W. De Langen, Adrianus J. Okamoto, Isamu Cho, Byoung Chul Smith, Paul Mensi, Ilhem Ambrose, Helen Kraljevic, Silvija Maidment, Julie Chmielecki, Juliann Li-Sucholeiki, Xiaocheng Doughton, Gail Patel, Gargi Jewsbury, Phil Szekeres, Phil Riess, Jonathan W.